Treatment-emergent effects may predict benefit from endocrine therapy.
Henry, N Lynn; Stearns, Vered.
J Clin Oncol
; 31(18): 2233-5, 2013 Jun 20.
Artigo em Inglês | MEDLINE | ID: mdl-23610120
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Adjuvant ovarian suppression in premenopausal breast cancer.
Toremifene versus tamoxifen for advanced breast cancer.
Extended Endocrine Therapy: Is 5 Years Enough?
Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer.
A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.